Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
https://unsplash.com/photos/_jbClosDsD4

Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors

The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…

Continue Reading Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors

HAE Junior’s Drawing Exhibition Unveiled the Dreams and Ambitions of Children Living With Hereditary Angioedema

HAE Junior’s drawing exhibition unveiled the dreams, wishes, and ambitions of children & teenagers living with hereditary angioedema (HAE). The patient organization HAE Junior organized a drawing exhibition named We…

Continue Reading HAE Junior’s Drawing Exhibition Unveiled the Dreams and Ambitions of Children Living With Hereditary Angioedema